Tevogen gains after it reaffirms revenue forecast for experimental oncology drugs

Tevogen

28/04/2025 21:57

** Shares of drug developer Tevogen TVGN.O up 49.35% at $1.40 in after-market trading

** Company reaffirms top-line revenue forecast for its experimental oncology drugs

** Projects $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion

** Stock down 9% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))